

COVID-19 VACCINES

COVID-19 Vaccines: An overview prepared by EAHP

This is a summary compiled by EAHP on publicly available information on the main COVID-19 vaccines which are currently being developed. Read the latest version **updated on 17 March 2021** [HERE](#) ^[1]

European Medicines Agency

The European Medicines Agency (EMA) has made published the following information for authorised COVID-19 vaccines: the assessment report of the Committee for Medicinal Products for Human Use (CHMP), the medicines overview (translated in all EU languages), the product information (translated in all EU languages) and the full body of the core Risk Management Plan.

Access this information for:

- [Comirnaty](#) ^[2]
- [COVID-19 Vaccine Moderna](#) ^[3]
- [COVID-19 Vaccine AstraZeneca](#) ^[4] (**Vaxzevria**)
- [COVID-19 Vaccine Janssen](#) ^[5]

For Comirnaty, EMA has made available additional information: [Information on extra dose from vials of Comirnaty COVID-19 vaccine](#) ^[6] | [Clarification of Comirnaty dosage interval](#) ^[7]

For Vaxzevria, EMA has made available additional information: [EMA Conclusion on COVID-19 Vaccine AstraZeneca and blood clots](#) ^[8] (including information for healthcare professionals) | [EMA Communication: AstraZeneca COVID-19 vaccine: review of very rare cases of unusual blood clots continues](#) ^[9] | [EMA - COVID-19 Vaccine AstraZeneca: Direct Healthcare Professionals Communication \(DHPC\) on risk of thrombocytopenia and coagulation disorders](#) ^[10]

Safety updates are regularly published for all approved vaccines:

- Comirnaty - [1st safety update](#) [11] | [29 March safety update](#) [12]
- COVID-19 Vaccine Moderna - [29 March safety update](#) [13]
- Vaxzevria - [29 March safety update](#) [14]
- COVID-19 Vaccine Janssen

EMA has made available an array of information on COVID-19, including information on treatments and vaccines.

- [COVID-19 vaccines: key facts](#) [15]
- [COVID-19 vaccines: development, evaluation, approval and monitoring](#) [16]
- [COVID-19 vaccines: studies for approval](#) [17]

A public stakeholder meeting on COVID-19 vaccines was organised by EMA on 11 December 2020. The recording of this meeting and all materials are available [HERE](#) [18].

A second public stakeholder meeting on COVID-19 vaccines was held on 8 January 2021. Find all information [HERE](#) [19].

EMA organized a third public stakeholder meeting on COVID-19 vaccines on 26 March 2021. Find all information [HERE](#) [20].

European Commission

- [Wepagge on safe COVID-19 vaccines for Europeans](#) [21]
The webpage contains information about how vaccines work, the health benefits of vaccines, the authorisation process, their long-term safety and the EU's current portfolio. The information on the webpage is translated into all EU languages.

European Vaccination Information Portal (EVIP)

- [Dedicated section on COVID-19 vaccines](#) [22]
The EVIP dedicated section shares information on the benefits of COVID-19 vaccines. Translations into all EU languages are available.

The disclaimer for the EAHP COVID-19 Resource Centre can be found [here](#) [23]

Last update: 9 April 2021

Links

[1] https://www.eahp.eu/sites/default/files/covid-19_vaccines_an_overview_prepared_by_eahp_march.pdf
 [2] <https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty> [3]
<https://www.ema.europa.eu/en/medicines/human/summaries-opinion/covid-19-vaccine-moderna> [4]
<https://www.ema.europa.eu/en/medicines/human/summaries-opinion/covid-19-vaccine-astrazeneca> [5]
<https://www.ema.europa.eu/en/medicines/human/EPAR/covid-19-vaccine-janssen> [6]
<https://www.ema.europa.eu/en/news/extra-dose-vials-comirnaty-covid-19-vaccine> [7]
<https://www.ema.europa.eu/en/news/clarification-comirnaty-dosage-interval> [8]
<https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-benefits-still-outweigh-risks-despite-possible-link-rare-blood-clots> [9] <https://www.ema.europa.eu/en/news/astrazeneca-covid-19-vaccine-review-very-rare-cases-unusual-blood-clots-continues> [10]
https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-covid-19-vaccine-astrazeneca-risk-thrombocytopenia_en.pdf [11]

<https://www.ema.europa.eu/en/news/first-covid-19-vaccine-safety-update-published> [12]
https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-comirnaty-29-march-2021_en.pdf [13] https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-covid-19-vaccine-moderna-29-march-2021_en.pdf [14] https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-29-march-2021_en.pdf [15]
<https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-vaccines-key-facts> [16] <https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-vaccines-development-evaluation-approval-monitoring> [17] <https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-vaccines-studies-approval> [18] <https://www.ema.europa.eu/en/events/public-stakeholder-meeting-development-authorisation-safe-effective-covid-19-vaccines-eu> [19]
<https://www.ema.europa.eu/en/events/public-stakeholder-meeting-approval-roll-out-covid-19-vaccines-eu> [20] <https://www.ema.europa.eu/en/events/public-stakeholder-meeting-approval-safety-monitoring-impact-covid-19-vaccines-eu> [21] https://ec.europa.eu/info/live-work-travel-eu/coronavirus-response/safe-covid-19-vaccines-europeans_en [22] <https://vaccination-info.eu/en/covid-19> [23] <https://www.eahp.eu/hp-practice/hospital-pharmacy/eahp-covid-19-resource-centre>